Pharma Strategy Blog

It is a bit of a shock to realise that this is my 200th blog post and 25,000 views since the first one, how time flies!

This month sees a couple of really interesting conferences that I'll be attending, Twittering and live blogging.  Both are from Eye for Pharma.  The first one is on March 18-19th in Princeton and will cover the 2nd Global Business Intelligence Summit meeting, including areas such as drug pipelines, emerging markets and the global economic downturn.

A number of industry speakers in the competitive intelligence field will be speaking on key topics including representatives from Merck, sanofi-aventis, Amgen, Wyeth, Bayer, Genzyme and Shire among others.  It looks to be a very topical and interesting conference overall.

The second meeting I'm looking forward to covering live is also from Eye for Pharma, this time the first Oncology Summit from Boston on March 30-31.  Topics covered include a range of subjects from product commercialisation strategies, regulatory environment, reimbursement, pricing and market access.

I've already interviewed Steve Heller from Johnson & Johnson on how biomarkers can influence and add value to the new product commercialisation of cancer drugs and will be posting the interview here on the blog this week, so watch this space.